Multiple Myeloma | Specialty

The OncLive Multiple Myeloma condition center page is a comprehensive resource for clinical news and expert insights on multiple myeloma and how to treat patients with monoclonal antibodies, proteasome inhibitors, bispecific T-cell engagers, immunomodulatory agents, CAR T-cell therapy, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in multiple myeloma.

Isatuximab Plus VRd Wins EU Approval for Newly Diagnosed, Transplant-Ineligible Multiple Myeloma

January 22nd 2025

The EMA’s CHMP has approved isatuximab in combination with VRd for transplant-ineligible patients with newly diagnosed multiple myeloma.

Dr Rifkin on the Role of Belantamab Mafodotin in Relapsed/Refractory Multiple Myeloma

January 21st 2025

Robert M. Rifkin, MD, FACP, offers advice to colleagues about belantamab mafodotin as a treatment option for patients with relapsed/refractory multiple myeloma.

CAR T and Evolving Treatment Paradigms for Early R/R MM

January 21st 2025

Panelists discuss the evolution of chimeric antigen receptor (CAR) T-cell therapy for patients with relapsed/refractory multiple myeloma (R/R MM), the factors that inform its use, and how treatment approaches differ for standard-risk vs functional high-risk patients.

Dr Banerjee on Bispecific Antibody Treatment De-Escalation Strategies in Relapsed Myeloma

January 20th 2025

Rahul Banerjee, MD, FACP, discusses treatment de-escalation strategies with the use of bispecific antibodies in patients with relapsed multiple myeloma.

Retrospective Study Highlights Real-World Uptake of Bispecific Antibodies in R/R Multiple Myeloma

January 19th 2025

Ira Zackon, MD, discusses real-world observational data on bispecific antibody use in community oncology in patients with relapsed/refractory multiple myeloma.

Preliminary Efficacy, Safety Data Drive Further Exploration of Mezigdomide-Based Combinations in R/R Myeloma

January 17th 2025

David S. Siegel, MD, PhD, discusses early safety and efficacy data that support further development of mezigdomide-based combinations in multiple myeloma.

Dr Ali on the Need for Novel Targets Beyond BCMA in Multiple Myeloma

January 15th 2025

Syed Abbas Ali, MBBS, discusses the identification of novel targets for patients with multiple myeloma who previously progressed on BCMA-targeted agents.

Future Considerations for Front-line Treatment of Newly Diagnosed Transplant Ineligible Multiple Myeloma

January 14th 2025

Panelists discuss how the future treatment landscape for transplant-ineligible/deferred NDMM is evolving toward more personalized approaches with quadruplet regimens, while acknowledging remaining challenges in optimizing duration of therapy, managing toxicities, and improving access to novel combinations.

Isatuximab Plus Pomalidomide and Dexamethasone Receives Approval in China for Relapsed/Refractory Multiple Myeloma

January 13th 2025

China’s NMPA has approved isatuximab plus pomalidomide and dexamethasone in adult patients with pretreated multiple myeloma.

The OncFive: Top Oncology Articles for the Week of 1/5

January 11th 2025

Sunvozertinib gets priority review in EGFR-mutated NSCLC, iparomlimab/tuvonralimab combination elicits responses in cervical cancer, and more.

Subcutaneous Isatuximab Plus Pd Meets Coprimary End Points, Proves Noninferior to IV Administration in R/R Multiple Myeloma

January 9th 2025

Subcutaneous isatuximab plus Pd led to a noninferior ORR and observed concentration before dosing at steady state vs IV isatuximab plus Pd in RRMM.

Academic Perspectives in Front-Line Treatment Goals in Newly Diagnosed Transplant-Ineligible Multiple Myeloma

January 7th 2025

Panelists discuss how patient selection for quadruplet therapy in transplant-ineligible/deferred NDMM requires careful consideration of multiple factors, including fitness level and comorbidities, while highlighting daratumumab-VRd’s potential advantages such as subcutaneous administration and demonstrated efficacy in the CEPHEUS trial despite increased complexity and cost considerations.

Anito-Cel Demonstrates Safety and Early Efficacy in R/R Multiple Myeloma

January 6th 2025

Anitocabtagene autoleucel generated durable response in patients with relapsed/refractory multiple myeloma.

Working on the Frontlines of a Revolution in Multiple Myeloma Care

December 30th 2024

A Mayo Clinic “lifer” who did not consider medicine as a career path until his later teenage years grew into a powerhouse who touched nearly every aspect of the multiple myeloma field, and he continues to push the boundaries of what is possible.

Emerging Updates in Front-line Treatment of Newly Diagnosed Transplant Ineligible Multiple Myeloma: Discussion of the CEPHEUS Trial.

December 24th 2024

Panelists discuss how current treatment approaches for transplant-ineligible newly diagnosed multiple myeloma patients are evolving with the addition of anti-CD38 therapies to standard VRd backbone, while examining unmet needs and the role of MRD negativity as an endpoint through recent trial data including CEPHEUS.

Dr Bishop on 34-Month Data With Anitocabtagene Autoleucel in R/R Myeloma

December 23rd 2024

Michael R. Bishop, MD, discusses 34-month data from the iMMagine-1 trial of anitocabtagene autoleucel in relapsed/refractory myeloma.

Dr Shah on the Effects of IVIG on Teclistamab-Associated Infection Risk in Myeloma

December 20th 2024

Mansi R. Shah, MD, on the effects of IVIG on infections in recipients of teclistamab therapy for multiple myeloma.

The OncFive: Top Oncology Articles for the Week of 12/8

December 14th 2024

Fixed-duration acalabrutinib combination improves PFS in CLL, imlunestrant ± abemaciclib boosts PFS in ESR1-mutated ER+ breast cancer, and more.

Cilta-Cel Leads to 100% MRD-Negativity Rate in High-Risk Smoldering Multiple Myeloma

December 11th 2024

Cilta-cel without induction therapy in high-risk smoldering myeloma marked the first study of CAR T-cell therapy in a precursor cancer setting.

Anitocabtagene Autoleucel Elicits Deep Responses in Relapsed/Refractory Multiple Myeloma

December 11th 2024

Anito-cel elicited an ORR of 97% with acceptable safety in patients with relapsed or refractory multiple myeloma.